These considerations suggested PTEN might also be a determinant of the efficacy of EGFR TKIs in EGFR wild-type tumours and prompted us to evaluate PTEN and PIK3CA gene copy number in our gefitinib-treated patients. Here, PIK3CA is linked to neoplasm.